Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Protox Therapeutics Inc T.PRX



TSX:PRX - Post by User

Protox Therapeutics Inc > SPA
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by NGLsRgood$on Aug 25, 2011 12:59pm
376 Views
Post# 18978958

RE: RE: SPA

RE: RE: SPAI think our management has forsaken it's shareholders. No clinical update in almost a year....what are they spending money on? ...new office furniture? Either tell us what's going on or take the company private...its unfair to shareholder to have to speculate each quarter as to what progress is being made. Compared to the releases Nymox puts out this company is pathetic. My recommendation is for all of us to email J. Beesely (investor relations) at ir@protoxtherapeutics
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities